• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Confine or Seclude Participants in Bioequivalence Trials, FDA Guidance Says

Confine or Seclude Participants in Bioequivalence Trials, FDA Guidance Says

January 18, 2021

Sponsors of generic drug products that need to conduct bioequivalence (BE) trials during the COVID-19 pandemic should develop site-specific plans to either quarantine or separate participants to minimize their exposure to the virus, according to a final guidance released by the FDA last week.

The guidance, intended to be in effect only for the duration of the public health emergency, directs sponsors that want to start or resume BE studies interrupted by the pandemic to use one of two trial models.

The first, a confinement or “bubble” design, confines staff and participants to the trial facility for the duration of the trial. The second nonconfinement, or “ambulatory,” design schedules procedures at times and locations so that no two participants come into contact and there is time to clean equipment and facilities between visits.

Comments on the guidance may be submitted at any time.

Read the guidance at https://bit.ly/35JMNnz.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing